Oral platelet glycoprotein IIb/IIIa inhibition L. Kristin NewbyDarren K. McGuire OriginalPaper Pages: 372 - 377
Platelet activation in acute myocardial infarction and the rationale for combination therapy Ian Conde-PozziNeal S. Kleiman OriginalPaper Pages: 378 - 385
Antithrombotic therapy in the cardiac catheterization laboratory: Focus on antiplatelet agents Mark I. FurmanAndrew L. Frelinger IIIAlan D. Michelson OriginalPaper Pages: 386 - 394
Novel inhibitors of factor X for use in cardiovascular diseases Frederick A. SpencerRichard C. Becker OriginalPaper Pages: 395 - 404
Treatment strategies for microvascular dysfunction following acute myocardial infarction Matthew T. Roe OriginalPaper Pages: 405 - 410
Issues and challenges with antithrombotic therapy in diabetic patients with acute coronary syndromes Gregory W. Barsness OriginalPaper Pages: 411 - 418
Global risk assessment for lipid therapy to prevent coronary heart disease Caitlin M. NassStephen D. WiviottRoger S. Blumenthal OriginalPaper Pages: 424 - 432
Primary prevention of coronary heart disease: Implications of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) Alan S. Brown OriginalPaper Pages: 439 - 444
The Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto miocardio (GISSI)-Prevenzione trial on fish oil and vitamin E supplementation in myocardial infarction survivors Neil J. Stone OriginalPaper Pages: 445 - 451
The role of fibric acid derivatives in the secondary prevention of coronary heart disease Jonathan KrakoffB. Sylvia VelaEliot A. Brinton OriginalPaper Pages: 452 - 458
Diastolic heart failure in the community Chari Y. T. HartMargaret M. Redfield OriginalPaper Pages: 461 - 469
Asymptomatic left ventricular dysfunction in the community Theresa A. McDonagh OriginalPaper Pages: 470 - 474
Genetic abnormalities responsible for dilated cardiomyopathy Jeffrey A. TowbinNeil E. Bowles OriginalPaper Pages: 475 - 480
